[Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital]

C Bessy; T Blin; E Pichon; S Marchand-Adam; D Carmier

doi:10.1016/j.rmr.2022.12.002

[Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital]

Rev Mal Respir. 2023 Jan;40(1):17-23. doi: 10.1016/j.rmr.2022.12.002. Epub 2022 Dec 22.

[Article in French]

Authors

C Bessy¹, T Blin², E Pichon², S Marchand-Adam³, D Carmier²

Affiliations

¹ CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, 2, Boulevard Tonnelé, 37000 Tours, France. Electronic address: corentin.bessy@gmail.com.
² CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, 2, Boulevard Tonnelé, 37000 Tours, France.
³ CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, 2, Boulevard Tonnelé, 37000 Tours, France; Université François Rabelais, centre d'étude des pathologies respiratoires (CEPR), Inserm U1100, faculté de médecine, Tours, France.

PMID: 36566134
DOI: 10.1016/j.rmr.2022.12.002

Abstract

Following the CodeBreak 100 study, since 2021 sotorasib has been available in France, with authorization for early access in treatment of non-small cell lung cancer with a KRAS G12C mutation. Our retrospective observational study was designed to determine the efficacy and safety of sotorasib under real-life conditions in patients treated at the Tours CHRU. Our study of 15 patients showed sotorasib to be effective in 47% of cases, with overall survival of 4 months and median progression-free survival of 5.5 months for responders. Tumor control was achieved in 7/8 (87%) of patients with PS of 0 or 1 and in 1/7 (14%) of patients with a PS of 2 or greater. Grade 3 acute hepatitis occurred in 3/15 patients (20%). While sotorasib is an interesting therapeutic option, with efficacy that seems better in patients in good general condition, it entails a possible risk of drug-induced hepatitis, which remains to be specified in dedicated studies.

Keywords: Cancer pulmonaire; Hépatite auto-immune; Immune hepatitis; KRAS; Lung cancer; Sotorasib.

Publication types

English Abstract
Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Hospitals, University
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation
Observational Studies as Topic
Proto-Oncogene Proteins p21(ras) / genetics

Substances

sotorasib
Proto-Oncogene Proteins p21(ras)
KRAS protein, human